|
US7468365B2
(en)
|
2000-11-17 |
2008-12-23 |
Eli Lilly And Company |
Lactam compound
|
|
SE0101004D0
(sv)
|
2001-03-21 |
2001-03-21 |
Astrazeneca Ab |
New measuring technique
|
|
RS56037B1
(sr)
|
2004-06-24 |
2017-09-29 |
Vertex Pharma |
Modulatori atp-vezujućih kasetnih transportera
|
|
EP3219705B1
(en)
|
2005-12-28 |
2020-03-11 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
CA2644136A1
(en)
*
|
2006-02-27 |
2007-09-07 |
The Johns Hopkins University |
Cancer treatment with gamma-secretase inhibitors
|
|
US7645789B2
(en)
|
2006-04-07 |
2010-01-12 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
|
EP2674428B1
(en)
|
2006-04-07 |
2016-04-06 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
|
EP3683218B1
(en)
|
2007-12-07 |
2024-09-18 |
Vertex Pharmaceuticals Incorporated |
Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
|
|
US8299059B2
(en)
|
2009-10-30 |
2012-10-30 |
Eli Lilly And Company |
Crystalline compound and a process for its preparation
|
|
PT3030568T
(pt)
|
2013-08-08 |
2018-12-24 |
Galapagos Nv |
Tieno[2,3-c]piranos como moduladores de cftr
|
|
EP2932966A1
(en)
|
2014-04-16 |
2015-10-21 |
Novartis AG |
Gamma secretase inhibitors for treating respiratory diseases
|
|
MA41051B1
(fr)
|
2014-10-06 |
2020-11-30 |
Vertex Pharma |
Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose
|
|
US10392378B2
(en)
|
2014-12-23 |
2019-08-27 |
Proteostasis Therapeutics, Inc. |
Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
|
US10548878B2
(en)
|
2015-07-24 |
2020-02-04 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods of increasing CFTR activity
|
|
BR112018007021B1
(pt)
|
2015-10-06 |
2024-01-09 |
Proteostasis Therapeutics, Inc |
Composto, composição compreendendo os ditos compostos e uso dos mesmos para tratar fibrose cística
|
|
US9890149B2
(en)
|
2015-10-07 |
2018-02-13 |
NuBridge BioSciences |
Isothiazole derivatives as CFTR modulators
|
|
BR112018007161B1
(pt)
|
2015-10-09 |
2024-01-16 |
Galapagos Nv |
COMPOSTOS PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDA N-SULFONILADA, COMPOSIÇÃO FARMACÊUTICA CONTENDO OS DITOS COMPOSTOS E USOS DOS MESMOS PARA TRATAR FIBROSE CÍSTICA
|
|
AU2017256172A1
(en)
|
2016-04-26 |
2018-09-06 |
AbbVie S.à.r.l. |
Modulators of cystic fibrosis transmembrane conductance regulator protein
|
|
US10138227B2
(en)
|
2016-06-03 |
2018-11-27 |
Abbvie S.Á.R.L. |
Heteroaryl substituted pyridines and methods of use
|
|
TW201811766A
(zh)
|
2016-08-29 |
2018-04-01 |
瑞士商諾華公司 |
N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
|
|
US10399940B2
(en)
|
2016-10-07 |
2019-09-03 |
Abbvie S.Á.R.L. |
Substituted pyrrolidines and methods of use
|
|
MX387203B
(es)
|
2016-11-18 |
2025-03-18 |
Cystic Fibrosis Found |
Pirrolopirimidinas como potenciadores de cftr.
|
|
SG10201911076QA
(en)
|
2016-12-16 |
2020-01-30 |
Cystic Fibrosis Found |
Bycyclic heteroaryl derivatives as cftr potentiators
|
|
IL268349B2
(en)
*
|
2017-02-17 |
2024-08-01 |
Hutchinson Fred Cancer Res |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
|
TW201831471A
(zh)
|
2017-02-24 |
2018-09-01 |
盧森堡商艾伯維公司 |
囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
|
|
KR20250030524A
(ko)
|
2019-08-09 |
2025-03-05 |
화이자 인코포레이티드 |
(s)-2-(((s)-6,8-디플루오로-1,2,3,4-테트라하이드로나프탈렌-2-일)아미노)-n-(1-(2-메틸-1-(네오펜틸아미노)프로판-2-일)-1h-이미다졸-4-일)펜탄아미드의고체 상태 형태 및 이의 용도
|